BeOne Medicines Ltd. (ONC)

Name: BeOne Medicines Ltd. (ONC) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Also trades as BEIGF. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

CIK 0001651308 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, BeOne Medicines Ltd. reported revenue of $5.34B. Revenue grew 40.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $6.13B.

Key ratios (year ended 2025-12-31)

87.5%

Gross margin

8.4%

Operating margin

5.4%

Net margin

6.6%

Return on year-end equity

40.2%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-15

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$6.13B	$5.34B	$3.81B	$2.46B	$1.42B	$1.18B	$308.87M	$428.21M	$198.22M	$238.39M	$1.07M
Cost of Revenue	n/a	n/a	n/a	n/a	$286.48M	$164.91M	$70.66M	$71.19M	$28.70M	$4.97M	$0
Gross Profit	$5.45B	$4.67B	$3.22B	$2.08B	$1.13B	$1.01B	$238.22M	$357.02M	$169.51M	n/a	n/a
R&D Expense	$2.29B	$2.15B	$1.95B	$1.78B	$1.64B	$1.46B	$1.29B	$927.34M	$679.00M	$269.02M	$98.03M
Operating Income	$923.10M	$447.14M	-$568.20M	-$1.21B	-$1.79B	-$1.44B	-$1.66B	-$959.89M	-$705.77M	-$98.46M	-$117.06M
Depreciation & Amortization	$154.93M	$141.69M	$171.76M	$87.67M	$66.28M	$46.46M	$31.79M	$18.62M	$10.39M	$4.76M	$1.91M
EBITDA	$1.08B	$588.82M	-$396.44M	-$1.12B	-$1.72B	-$1.39B	-$1.63B	-$941.27M	-$695.38M	-$93.70M	-$115.15M
Net Income	$655.71M	$286.93M	-$644.79M	-$881.71M	-$2.00B	-$1.46B	-$1.62B	-$948.63M	-$673.77M	-$93.11M	-$119.22M
EPS (Diluted)	n/a	$0.19	-$0.47	-$0.65	-$1.49	-$1.21	-$1.50	-$1.22	n/a	n/a	n/a
Total Assets	$9.18B	$8.19B	$5.92B	$5.81B	$6.38B	$8.54B	$5.60B	$1.61B	$2.25B	$1.05B	$405.81M
Total Liabilities	$4.00B	$3.83B	$2.59B	$2.27B	$2.00B	$2.40B	$1.73B	$633.93M	$496.04M	$362.25M	$52.91M
Long-Term Debt	$788.68M	$836.37M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shareholders' Equity	$5.17B	$4.36B	$3.33B	$3.54B	$4.38B	$6.13B	$3.87B	$962.21M	$1.74B	$669.81M	$352.91M
Cash & Equivalents	$5.10B	$4.55B	$2.63B	$3.17B	$3.87B	$4.38B	$1.38B	$618.01M	$712.94M	$239.60M	$87.51M
Operating Cash Flow	$1.48B	$1.13B	-$140.63M	-$1.16B	-$1.50B	-$1.30B	-$1.28B	-$750.27M	-$547.72M	$12.75M	-$89.51M
Capital Expenditures	$153.87M	$185.84M	$492.66M	$561.90M	$325.43M	$262.94M	$117.51M	$89.61M	$70.28M	$46.37M	$23.50M
Free Cash Flow	$1.33B	$941.74M	-$633.29M	-$1.72B	-$1.82B	-$1.56B	-$1.40B	-$839.88M	-$618.00M	-$33.62M	-$113.02M
Shares Outstanding	1.47B	1.44B	1.39B	1.36B	1.36B	1.33B	1.19B	801.34M	776.26M	592.07M	515.83M
Weighted Average Diluted Shares	n/a	1.47B	1.37B	1.36B	1.34B	1.21B	1.09B	780.70M	n/a	n/a	n/a
EPS (Basic)	n/a	$0.20	-$0.47	-$0.65	-$1.49	-$1.21	-$1.50	-$1.22	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView